Evidence map›Paper›PMID 29619870›Full record

SynthesisRenal failure2018

Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis.

Xuemei Liu, Tingting Zhai, Ruixia Ma, Congjuan Luo, Huifang Wang, Liqiu Liu

Open access · goldAbstract readEvaluation StudyMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Renal failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 4 pooled it
8.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xuemei Liua Department of Nephrology , The Affiliated Hospital of Qingdao University , Qingdao , China.
Tingting Zhaia Department of Nephrology , The Affiliated Hospital of Qingdao University , Qingdao , China.
Ruixia Maa Department of Nephrology , The Affiliated Hospital of Qingdao University , Qingdao , China.
Congjuan Luoa Department of Nephrology , The Affiliated Hospital of Qingdao University , Qingdao , China.
Huifang Wanga Department of Nephrology , The Affiliated Hospital of Qingdao University , Qingdao , China.
Liqiu Liua Department of Nephrology , The Affiliated Hospital of Qingdao University , Qingdao , China.
Qingdao University · CNAffiliated Hospital of Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWhether uric acid levels were associated with the progression of chronic kidney disease (CKD) remained controversial. This meta-analysis was aimed to assess the effect of lowering serum uric acid therapy on the progression of CKD to clarify the role of uric acid in the progression of CKD indirectly.

methodsPubmed, Embase, the Cochrane library, CBM were searched for randomized controlled trials (RCTs) that assessed the efficiency of lowering serum uric acid therapy on the progression of CKD without language restriction. Summary estimates of weighted mean differences (WMDs) and relative risk (RR) were obtained by using random-effect or fixed-effect models. Sensitivity analyses were performed to identify the source of heterogeneity.

resultsA total of 12 randomized controlled trials with 832 CKD participants were included in the analysis. Pooled estimate for eGFR was in favor of lowering serum uric acid therapy with a mean difference (MD) of 3.88 ml/min/1.73 m

conclusionsUric acid-lowering therapy may be effective in retarding the progression of CKD. Further randomized controlled trials should be performed to confirm the effect of lowering serum uric acid therapy on the progression of CKD.

Indexed as

CreatinineDisease ProgressionGlomerular Filtration RateHumansHyperuricemiaKidneyRandomized Controlled Trials as TopicRenal Insufficiency, ChronicTreatment OutcomeUric AcidUricosuric AgentsCreatinineUric AcidUricosuric Agentschronic kidney diseaserandomized controlled trialsUric aciduric acid-lowering therapy

Identifiers

PMID29619870
PMCPMC6014338
OpenAlexW2795910617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.